The lym Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the lym Hub cannot guarantee the accuracy of translated content. The lym and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Lymphoma & CLL Hub is an independent medical education platform, sponsored by Beigene, Johnson & Johnson and Roche, and supported through educational grants from Bristol Myers Squibb, Incyte, Lilly, and Pfizer. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View lym content recommended for you
Zanubrutinib receives FDA approval for CLL and SLL
On January 19, 2023, it was announced that the U.S. Food and Drug Administration (FDA) had granted approval to zanubrutinib, a Bruton’s tyrosine kinase inhibitor, for the treatment of adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).1
The approval is based on key data obtained from the SEQUOIA trial (NCT03336333), which compared zanubrutinib with bendamustine + rituximab in patients with previously untreated CLL or SLL, and the ALPINE trial (NCT03734016), which compared zanubrutinib with ibrutinib in patients with relapsed or refractory (R/R) CLL or SLL.
Both trials demonstrated improved efficacy and an acceptable safety profile for zanubrutinib in CLL/SLL.
- In the SEQUOIA trial, zanubrutinib showed a significant progression-free survival benefit versus bendamustine + rituximab
- In the ALPINE trial, zanubrutinib demonstrated a superior overall response rate compared with ibrutinib in R/R patients
- The overall safety profile of zanubrutinib therapy was consistent with previous studies in both trials
References
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content
